Keynote Financial Services’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.63M Sell
38,262
-1,005
-3% -$216K 4.51% 2
2026
Q1
$8.54M Sell
39,267
-146
-0.4% -$32.4K 4.54% 3
2025
Q4
$9.01M Sell
39,413
-1,192
-3% -$272K 5.04% 2
2025
Q3
$9.4M Sell
40,605
-275
-0.7% -$56K 5.67% 2
2025
Q2
$7.59M Buy
40,880
+144
+0.4% +$26.8K 5.1% 2
2025
Q1
$8.54M Sell
40,736
-263
-0.6% -$51.1K 6.09% 2
2024
Q4
$7.29M Buy
40,999
+246
+0.6% +$45.2K 5.59% 2
2024
Q3
$8.05M Sell
40,753
-293
-0.7% -$54.7K 6.15% 2
2024
Q2
$7.04M Buy
41,046
+264
+0.6% +$43.7K 5.89% 2
2024
Q1
$7.43M Buy
+40,782
New +$7.03M 6.23% 2

Other funds holding ABBV

Keynote Financial Services's ABBV Position: Q2 2026 in Review

Keynote Financial Services reduced its AbbVie (ABBV) stake by 2.6% in Q2 2026, selling an estimated $216K and leaving 38,262 shares worth $9.63M. The position accounts for 4.51% of the portfolio, ranked #2.

Keynote Financial Services first reported a position in ABBV in Q1 2024 and has held it in 10 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Keynote Financial Services held 38,262 shares of AbbVie worth $9.63M as of Q2 2026.
  • Keynote Financial Services sold 1,005 AbbVie shares in Q2 2026, an estimated $216K.
  • AbbVie made up 4.51% of Keynote Financial Services's portfolio in Q2 2026, its #2 holding.
  • Keynote Financial Services first reported a position in AbbVie in Q1 2024 and has held it in 10 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Keynote Financial Services's 13F filing for Q2 2026, filed 3 Aug 2026.